Value of Celecoxib Combined with Indomethacin Suppository in the Prevention of SAP
Objective:To explore the value of celecoxib combined with indomethacin suppository in the prevention of SAP.Methods:200 patients with AP in the hospital from January 2021 to January 2022 were selected as the study objects,and randomly divided into the conventional group(101 cases)and the experimental group(99 cases).The conventional group was treated with conventional treatment according to the latest guidelines for diagnosis and treatment of pancreatitis.The experimental group was treated with celecoxib on the basis of conventional treatment.Patients of the two groups were observed whether they could develop into SAP and whether there were local complications or not.Amylase,CRP,serum interleukin-6(IL-6)and tumor necrosis factor a(TNF-α)of two groups of patients,and the severity of multiple pancreatitis was scored.Results:Compared with the conventional group,the incidence of SAP in the experimental group was significantly reduced,and the late local complications were significantly reduced.The levels of amylase,IL-6 and TNF-α in the experimental group were significantly lower than those in the control group.The improvement of abdominal pain in the experimental group was more obvious than that in the conventional group.the hospital stays and total cost were significantly reduced,and the difference was statistically significant(P＜0.05).Conclusion:Celecoxib combined with indomethacin suppository is effective in preventing SAP.It can significantly reduce the inflammatory factors,greatly decrease SAP rate,and significantly reduce the hospitalization cost,reduce hospitalization time.
Severe pancreatitisCelecoxibIndometacinOrgan damageComplication
NETL
NSTL
万方数据
